Inc. (OTCBB: CTHP), a biotechnology business incubator, with a specific
emphasis on disruptive treatments and nanotechnology, announced today it anticipates
a definitive agreement to acquire a minority ownership share of NanoTherapies,
LLC will be finalized by the end of this month. The acquisition of a 25% stake
in NanoTherapies will be the first acquisition completed by Cancer Therapeutics.
NanoTherapies develops life-changing therapies for cancer treatment based on
an evolving set of intellectual properties and patents derived from the exploitation
of calcium phosphate nanoparticles for therapeutic and diagnostic applications.
Cancer Therapeutics, Inc., an emerging biotechnology business incubator with
a specific emphasis on disruptive cancer treatments and nanotechnology. It seeks
out disruptive cancer research and technology opportunities to invest in, develop,
and commercialize. The end result will be therapies, treatments, and pharmaceuticals
targeted at more efficiently and effectively attacking cancer. CTI seeks partners
to co-develop drugs in various stages in our pipeline.